account_balance
Investment manager · 13F filer · SEC CIK 1839948
TCG Crossover Management, LLC
Reported value$4.16Bas of Jun 30, 2026
Positions54 12 new, 7 sold out
Top 10 weight57.4%ABVX alone is 19%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
ABVXAbivax SA American Depositary Shares
19.2%Trimmed −7%
TNGXTango Therapeutics Inc
6.8%Trimmed −14%
CGONCg Oncology Inc
6.3%
COGTCogent Biosciences Inc
4.5%
IMVTImmunovant Inc
4.1%
SYRESpyre Therapeutics Inc
4.1%
DNTHDianthus Therapeutics Inc
3.9%
MIRMMirum Pharmaceuticals Inc
3.0%
ZLABZai Lab Ltd-adr
2.8%New
AMLXAmylyx Pharmaceuticals Inc
2.7%
GLUEMonte Rosa Therapeutics Inc
2.7%
BCRXBiocryst Pharmaceuticals Inc
2.6%
ABVXAbivax SA American Depositary Shares
19.2%Trimmed −7%
TNGX6.8%CGON6.3%COGT4.5%IMVT4.1%SYRE4.1%DNTH3.9%MIRM3.0%ZLAB2.8%AMLX2.7%GLUE2.7%BCRX2.6%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
ABVX Abivax SA American Depositary Shares 19.2% Trimmed −7%TNGX Tango Therapeutics Inc 6.8% Trimmed −14%CGON Cg Oncology Inc 6.3% HeldCOGT Cogent Biosciences Inc 4.5% HeldIMVT Immunovant Inc 4.1% HeldSYRE Spyre Therapeutics Inc 4.1% HeldDNTH Dianthus Therapeutics Inc 3.9% HeldMIRM Mirum Pharmaceuticals Inc 3.0% HeldZLAB Zai Lab Ltd-adr 2.8% NewAMLX Amylyx Pharmaceuticals Inc 2.7% HeldGLUE Monte Rosa Therapeutics Inc 2.7% HeldBCRX Biocryst Pharmaceuticals Inc 2.6% Held
What changed